Eupraxia Pharmaceuticals Inc.
HealthcareNASDAQ:EPRX · NASDAQ Global Market
+$0.01 today
Vol 0.14M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-65.6%
avg -174.9%
ROIC
-66.6%
avg -38.2%
ROA
-62.5%
avg -159.1%
Analysis
ROA is currently the strongest return metric at -62.5% versus its period average of -159.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James A. Helliwell FRCPC | Chief Executive Officer & Director | $673,916.00 | — | 52 | — | — |
Jeymi Tambiah | Chief Medical Officer | $578,000.00 | — | — | — | — |
Mark Kowalski | Chief Medical Officer | $578,000.00 | — | 71 | — | — |
Alexander John Rothwell | Chief Financial Officer | $410,522.00 | — | 57 | — | — |
Paul Anthony Brennan | Chief Corporate Development Officer | $362,543.00 | — | — | — | — |
Amanda Malone | Chief Scientific Officer & Chief Operating Officer | $330,495.00 | — | 45 | — | — |
Alex Therien | Executive VP of R&D | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Inventiva S.A.
NASDAQ:IVA
$200.13M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages EPRX?
Eupraxia Pharmaceuticals Inc. (EPRX) lists 7 active executives. The top listed executive is James A. Helliwell FRCPC, Chief Executive Officer & Director.
Explore More
Continue the stock analysis
Jump to another research area for this company.